Equillium Earnings Call Transcripts
Fiscal Year 2026
-
EQ504 and ABX464 are confirmed AhR modulators that induce miR-124 and anti-inflammatory cytokines in immune cells, improving barrier function and reducing inflammation. EQ504 is designed for high colon tissue exposure and will enter phase I trials mid-year, with CYP1A1 as a key biomarker.
-
EQ504, a selective AhR modulator with colon-specific delivery, targets key disease mechanisms in ulcerative colitis and is supported by strong preclinical and translational data. Phase I studies are set to begin mid-year in Australia, with a robust financial runway and plans for broader indication expansion.
Fiscal Year 2025
-
The event highlighted the scientific and clinical rationale for AHR modulation in ulcerative colitis, emphasizing EQ504’s dual action on immune regulation and tissue repair. Experts discussed strong preclinical and clinical data, strategic positioning for combination therapy, and plans for targeted colonic delivery to maximize efficacy and safety.
-
EQ504, a novel AhR modulator targeting ulcerative colitis, is advancing toward Phase I trials after a $50 million financing. Preclinical data show strong mucosal healing and cytokine induction, with clinical studies set to begin mid-2025.
-
The phase III EQUATOR study in first-line acute GVHD showed itolizumab did not meet the primary endpoint at day 29 but demonstrated significant long-term benefits, including higher complete response rates at day 99, longer duration of response, and improved failure-free survival, with a favorable safety profile. Regulatory discussions for accelerated approval are underway.
Fiscal Year 2024
-
Multiple clinical programs are advancing, including EQ101 for alopecia areata and EQ302 for GI diseases, with key data and milestones expected in 2025. The Ono partnership decision by October 30 could bring a $35 million payment and further reduce operating burn.
-
The company is awaiting a pivotal decision from Ono on the acquisition of itolizumab, which could bring significant funding and shape its strategic direction. Meanwhile, it advances its multi-cytokine platform, with EQ101 showing promising results in alopecia areata and EQ302 targeting GI diseases, both set for further clinical development in 2025.
-
Recent clinical data for EQ101 in alopecia areata showed promising efficacy in moderate to severe cases and a favorable safety profile, with plans for dose optimization in future studies. An upcoming interim analysis in acute GVHD will determine a major partnership milestone, potentially triggering significant payments and extending financial runway.